- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02352311
Safety and Pharmacokinetic Characteristics of DKF-313
July 1, 2021 updated by: Dongkook Pharmaceutical Co., Ltd.
A Randomized, Open-label, Single-dose, 2-treatment, 2-way, 2-period Crossover Study to Evaluate the Safety and the Pharmacokinetic Characteristics of DKF-313 in Healthy Male Volunteers
This is a randomized, open-label, single-dose, 2-treatment, 2-way, 2-period crossover study to evaluate the safety and the pharmacokinetic characteristics of DKF-313 (dutasteride and tadalafil) in healthy male volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is conducted to evaluate the pharmacokinetics of DKF-313 (dutasteride and tadalafil) comparing with the concomitant administration of AVODART and CIALIS in healthy male volunteers.
Study Type
Interventional
Enrollment (Actual)
54
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jeollabuk-do
-
Jeonju, Jeollabuk-do, Korea, Republic of, 561-712
- Chonbuk National University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 29 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Age 19 to 29 years
- BMI 17.5 to 30.5 kg/m2 and body weight 55 kg or more
- No congenital or chronic diseases within 3 years, no disease symptoms or findings
- Eligible according to the laboratory results of hematology, blood chemistry and urinalysis and ECG
- Voluntarily signed the informed consent form 6. Willing to participate in the study
Exclusion Criteria:
- Clinically significant disorders of blood, kidney, endocrine, respiratory system, gastrointestinal system, urology, cardiovascular system, liver, psychiatry, neurology or allergy
- Gastrointestinal diseases or surgery which may affect absorption of the investigational products
- ALT or AST > 2xULN
- Excessive alcohol consumption (> 210 g/week) within 6 months
- Participated and administered the investigational products in other clinical trial within 2 months
- SBP ≤ 100 mmHg or ≥ 150 mmHg or DBP ≤ 60 mmHg or ≥ 100 mmHg
- History or positive result of serious alcohol or drug abuse within 1 year
- Drugs which induce or inhibit drug metabolism within 1 month
- Smoked more than 10 cigarettes a day
- Prescribed drugs or over-the counter drugs within 10 days
- Donated whole blood within 2 months or apheresis within 1 month
- Severe acute/chronic medical and mental conditions or lab abnormalities which may increase the risk or interfere in the interpretation of study results
- Hypersensitivity to tadalafil or phosphodiesterase type 5 inhibitor, and dutasteride or 5-α reductase inhibitor, or other drugs including aspirin, antibiotics, etc.
- Galactose intolerance, fructose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
- CYP3A4 inhibitors or CYP3A4 inducers within 2 weeks
- Myocardial infarction within 90 days
- Unstable angina or angina during sexual intercourse
- Heart failure (New York Heart Association Class 2 or higher) within 6 months
- Uncontrolled arrhythmias
- Stroke within 6 months
- Inherited retinal degeneration including retinitis pigmentosa
- Vision loss in one eye due to non-arteritic anterior ischemic optic neuropathy (NAION)
- Plans to donate blood for at least 6 months after final dose of the investigational products
- Unwilling to comply with the lifestyle guidelines in the protocol
- Not eligible due to other reasons at the investigator's discretion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1 AVODART, CIALIS, DKF-313
In Period 1, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose.
In Period 2, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose.
|
Combination of dutasteride 0.5 mg and tadalafil 5 mg
Dutasteride 0.5 mg
Other Names:
Tadalafil 5 mg
Other Names:
|
Experimental: Arm 2 DKF-313, AVODART, CIALIS
In Period 1, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose.
In Period 2, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose.
|
Combination of dutasteride 0.5 mg and tadalafil 5 mg
Dutasteride 0.5 mg
Other Names:
Tadalafil 5 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUClast and Cmax of dutasteride and tadalafil
Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192 h
|
0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192 h
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Min-Gul Kim, M.D., Chonbuk National University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2015
Primary Completion (Actual)
June 1, 2015
Study Completion (Actual)
June 1, 2015
Study Registration Dates
First Submitted
January 22, 2015
First Submitted That Met QC Criteria
January 30, 2015
First Posted (Estimate)
February 2, 2015
Study Record Updates
Last Update Posted (Actual)
July 6, 2021
Last Update Submitted That Met QC Criteria
July 1, 2021
Last Verified
February 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Prostatic Diseases
- Prostatic Hyperplasia
- Hyperplasia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Urological Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Phosphodiesterase Inhibitors
- Phosphodiesterase 5 Inhibitors
- 5-alpha Reductase Inhibitors
- Tadalafil
- Dutasteride
Other Study ID Numbers
- DK-DT-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on DKF-313
-
Dongkook Pharmaceutical Co., Ltd.CompletedBenign Prostatic HyperplasiaKorea, Republic of
-
Dongkook Pharmaceutical Co., Ltd.RecruitingPeriodontal DiseasesKorea, Republic of
-
Sichuan Clover Biopharmaceuticals, Inc.CompletedMalignant Pleural EffusionChina
-
Phoenicis TherapeuticsTerminatedEpidermolysis Bullosa Dystrophica, Recessive | Epidermolysis Bullosa Dystrophica, DominantUnited States, Spain, France
-
Otonomy, Inc.CompletedSubjective TinnitusUnited States, United Kingdom, Germany, Poland
-
Otonomy, Inc.Completed
-
Wyeth is now a wholly owned subsidiary of PfizerSolvay PharmaceuticalsTerminated
-
Vaxxinity, Inc.Recruiting
-
Wyeth is now a wholly owned subsidiary of PfizerSolvay PharmaceuticalsTerminated
-
Wenzhou Medical UniversityRecruiting